Similar articles for PMID: 26423695

Year	Number of Results
1997	1
1999	2
2005	3
2007	3
2008	3
2009	2
2010	7
2011	8
2012	4
2013	9
2014	5
2015	7
2016	19
2017	11
2018	14
2019	16
2020	16
2021	10
2022	9
2023	3
2024	0

1

Past, Present, and Future of Targeting Ras for Cancer Therapies.

Tan Z, Zhang S. Tan Z, et al. Mini Rev Med Chem. 2016;16(5):345-57. doi: 10.2174/1389557515666151001154111. Mini Rev Med Chem. 2016. PMID: 26423695 Review.

2

Getting a Handle on RAS-targeted Therapies: Cysteine Directed Inhibitors.

Huynh MV, Campbell SL. Huynh MV, et al. Mini Rev Med Chem. 2016;16(5):383-90. doi: 10.2174/1389557515666151001154352. Mini Rev Med Chem. 2016. PMID: 26423694 Review.

3

PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.

Asati V, Mahapatra DK, Bharti SK. Asati V, et al. Eur J Med Chem. 2016 Feb 15;109:314-41. doi: 10.1016/j.ejmech.2016.01.012. Epub 2016 Jan 12. Eur J Med Chem. 2016. PMID: 26807863 Review.

4

The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?

Lv J, Wang J, Chang S, Liu M, Pang X. Lv J, et al. Acta Biochim Biophys Sin (Shanghai). 2016 Jan;48(1):17-26. doi: 10.1093/abbs/gmv102. Epub 2015 Oct 19. Acta Biochim Biophys Sin (Shanghai). 2016. PMID: 26487443 Free article. Review.

5

Biology, pathology, and therapeutic targeting of RAS.

Rhett JM, Khan I, O'Bryan JP. Rhett JM, et al. Adv Cancer Res. 2020;148:69-146. doi: 10.1016/bs.acr.2020.05.002. Epub 2020 Jul 9. Adv Cancer Res. 2020. PMID: 32723567 Free PMC article. Review.

6

PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.

Bouali S, Chrétien AS, Ramacci C, Rouyer M, Becuwe P, Merlin JL. Bouali S, et al. Oncol Rep. 2009 Mar;21(3):731-5. Oncol Rep. 2009. PMID: 19212633

7

Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.

Maira SM, Furet P, Stauffer F. Maira SM, et al. Future Med Chem. 2009 Apr;1(1):137-55. doi: 10.4155/fmc.09.5. Future Med Chem. 2009. PMID: 21426073 Review.

8

Direct Inhibitors of Ras-Effector Protein Interactions.

Upadhyaya P, Bedewy W, Pei D. Upadhyaya P, et al. Mini Rev Med Chem. 2016;16(5):376-82. doi: 10.2174/1389557515666151001141713. Mini Rev Med Chem. 2016. PMID: 26423701 Review.

9

Improving Prospects for Targeting RAS.

Singh H, Longo DL, Chabner BA. Singh H, et al. J Clin Oncol. 2015 Nov 1;33(31):3650-9. doi: 10.1200/JCO.2015.62.1052. Epub 2015 Sep 14. J Clin Oncol. 2015. PMID: 26371146 Review.

10

Challenges in Ras therapeutics in pancreatic cancer.

Choi M, Bien H, Mofunanya A, Powers S. Choi M, et al. Semin Cancer Biol. 2019 Feb;54:101-108. doi: 10.1016/j.semcancer.2017.11.015. Epub 2017 Nov 21. Semin Cancer Biol. 2019. PMID: 29170065 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

132 results

Results by year